Merck (MRK) Tops Q3 EPS by 31c, Revenues Beat; Narrows & Raises FY20 Non-GAAP EPS Guidance Above Consensus, Provides FY20 Revs. Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. RAY
10. BLK

Go back to Merck (MRK) Tops Q3 EPS by 31c, Revenues Beat; Narrows & Raises FY20 Non-GAAP EPS Guidance Above Consensus, Provides FY20 Revs. Outlook

Merck Announces Third-Quarter 2020 Financial Results

October 27, 2020 6:45 AM EDT

Third-Quarter 2020 Worldwide Sales Were $12.6 Billion, an Increase of 1%; Excluding the Impact from Foreign Exchange, Sales Grew 2% KEYTRUDA Sales Grew 21% to $3.7 Billion Animal Health Sales Grew 9% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 12% Third-Quarter 2020 GAAP EPS Was $1.16; Third-Quarter Non-GAAP EPS Was $1.74 Advanced and Expanded Broad Pipeline Announced Additional Positive Phase 3 Results for Investigational Pneumococcal Conjugate Vaccine (V114) in Adults Presented Phase 3 Data for Investigational Gefapixant in Development for Chronic Cough; Early Data for MK-4830 in Oncology and... More